Arbutus Biopharma Engages with Investors at London Conference
Arbutus Biopharma Engages with Investors at London Conference
Arbutus Biopharma Corporation (NASDAQ: ABUS) is making strides in the biopharmaceutical industry, focusing on developing innovative therapies for chronic hepatitis B virus (cHBV) infections. Known for its expertise in virology, the company is set to showcase its advancements at an upcoming investor event that promises to foster valuable connections and insights.
Upcoming Investor Conference Presentation
The Jefferies London Healthcare Conference will be a significant opportunity for Arbutus. Scheduled for November 21, 2024, at 12:00 pm GMT / 7:00 am EST, this event includes a fireside chat where company representatives will discuss their ongoing research and development efforts in detail.
Accessing the Live Webcast
For those interested, the live webcast of the fireside chat can be accessed through the Arbutus investor website. Attendees will have the chance to listen to key insights shared by the company. Following the event, the recorded webcast will also be available on their website for catch-up viewing.
About Arbutus Biopharma Corporation
Arbutus Biopharma is driven by a commitment to uncover effective treatments for patients suffering from chronic hepatitis B. This clinical-stage biopharmaceutical company is focusing on levers that can potentially push the boundaries of traditional therapy. Their strategy involves a robust pipeline that showcases unique compounds, including an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor known as AB-101.
Innovative Therapeutics in Development
Imdusiran is currently under investigation in two Phase 2a combination clinical trials. This promising compound has shown encouraging clinical data, illustrating its ability to reduce surface antigen levels and rekindle the immune response specific to HBV. On the other hand, AB-101 is being examined in a Phase 1a/1b clinical trial, highlighting the company's dedication to exploring multiple avenues for cHBV treatment.
Contacting Arbutus Biopharma
For investor relations inquiries or media queries, Lisa M. Caperelli, Vice President of Investor Relations, is available for contact. Interested parties can reach her at 215-206-1822 or via email, providing a direct line to the company’s communication channel.
Frequently Asked Questions
What is Arbutus Biopharma’s main focus?
Arbutus Biopharma focuses on developing therapies for chronic hepatitis B virus (cHBV) infections.
When is Arbutus Biopharma’s conference presentation?
The conference presentation is set for November 21, 2024, at 12:00 pm GMT / 7:00 am EST.
How can I access the live webcast of the presentation?
The live webcast can be accessed through the Arbutus investor website during the conference.
What is the significance of imdusiran?
Imdusiran is a key component in Arbutus’s pipeline, showing potential in reducing surface antigen levels and enhancing immune responses against HBV.
Who can I contact for more information about Arbutus Biopharma?
Lisa M. Caperelli, the Vice President of Investor Relations, can be contacted for more information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.